2025
Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years
Margot N, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen L, Ling J, Singh R, Dvory-Sobol H, Ogbuagu O, Segal-Maurer S, Molina J, Rhee M, Callebaut C. Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years. The Journal Of Infectious Diseases 2025, jiaf050. PMID: 39873394, DOI: 10.1093/infdis/jiaf050.Peer-Reviewed Original ResearchOptimized background regimenHIV-1HIV-1 RNA <HIV-1 RNA suppressionTreatment-experienced peopleTandem liquid chromatography/mass spectrometryFirst-in-class inhibitorResistant to 2HIV-1 capsidBackground regimenTreatment-experiencedVirological failureLenacapavirRNA suppressionDrug classesDrug measurementsResistance assaysMonotherapyPWHLiquid chromatography/mass spectrometryTreatmentDrugResistance analysisResuppressionYears
2024
Short Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis
Joseph M, Krishna M, Ezenna C, Pereira V, Ismayl M, Nanna M, Bangalore S, Goldsweig A. Short Versus One-Year Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: an Updated Meta-Analysis. The American Journal Of Cardiology 2024, 237: 17-28. PMID: 39577682, DOI: 10.1016/j.amjcard.2024.10.038.Peer-Reviewed Original ResearchPost-percutaneous coronary interventionAcute coronary syndromeDrug-eluting stentsPercutaneous coronary interventionCoronary interventionAcute coronary syndrome cohortCochrane Central databasesShortening DAPT durationMonths post-percutaneous coronary interventionClopidogrel subgroupRandomized controlled trialsNo significant differenceCoronary syndromeMonotherapyTicagrelor monotherapyDAPT durationShorter DAPTBleedingStent thrombosisP2Y12iMyocardial infarctionControlled trialsSubgroup interactionsDAPTMeta-analysis649 A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer
Chung C, Dimitrios Colevas A, Adkins D, Rodriguez C, Park J, Gibson M, Sukari A, Worden F, Johnson F, Saba N, Burtness B, Julian R, Bauman J, Jotte R, Seiwert T, Dunn L, Chaney M, Agensky L, Goel A, Levisetti M, Margossian S, Quayle S, Pai S. 649 A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer. 2024, a745-a745. DOI: 10.1136/jitc-2024-sitc2024.0649.Peer-Reviewed Original ResearchCost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 2024, 145: 127-140. PMID: 39374533, PMCID: PMC11738035, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcomeA Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer
Morgensztern D, Ready N, Johnson M, Dowlati A, Choudhury N, Carbone D, Schaefer E, Arnold S, Puri S, Piotrowska Z, Hegde A, Chiang A, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson R, Hingorani P, Jeng E, Furqan M. A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer. Clinical Cancer Research 2024, 30: 5042-5052. PMID: 39287821, PMCID: PMC11565168, DOI: 10.1158/1078-0432.ccr-24-1547.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerRelapsed/refractory small cell lung cancerTreatment-emergent adverse eventsCell lung cancerAdverse eventsLung cancerVeno-occlusive liver diseaseAntitumor activityResponse rateMedian response durationProgression-free survivalMaximum tolerated doseDose-expansion cohortPhase I studyIncreased aspartate aminotransferaseAntibody-drug conjugatesWeeks' monotherapyDose escalationPrior therapyTolerated doseMedian ageResponse durationLiver diseaseMonotherapyPatients632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Lin C, Schneider R, Gutierrez M, Shen L, Chung K, Doroshow D, Gao B, Millward M, Hsieh C, Xu C, Cai S, Tian Y, Liu L, Shen C, Tan Y, He Y, Zhang C, Li L, Ma M, Xu L. 632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors. Annals Of Oncology 2024, 35: s503-s504. DOI: 10.1016/j.annonc.2024.08.699.Peer-Reviewed Original ResearchValemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
Maruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s229. DOI: 10.1016/s2152-2650(24)00908-x.Peer-Reviewed Original ResearchChemotherapy and Targeted Therapies, Biological Therapies for Renal Cell Carcinoma
Malhotra J, Meza L, Govindarajan A, Pal S. Chemotherapy and Targeted Therapies, Biological Therapies for Renal Cell Carcinoma. 2024, 1-15. DOI: 10.1007/978-3-030-51192-0_98-1.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaOverall survivalTreatment landscapeCell carcinomaTargeted therapyTreatment landscape of metastatic renal cell carcinomaSystemic therapyCombination therapyBiologic therapyTreatment optionsTherapyCarcinomaTreatmentSurvivalMonotherapyImmunotherapyChemotherapyInhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
Mukohara T, Park Y, Sommerhalder D, Yonemori K, Hamilton E, Kim S, Kim J, Iwata H, Yamashita T, Layman R, Mita M, Clay T, Chae Y, Oakman C, Yan F, Kim G, Im S, Lindeman G, Rugo H, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso P. Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial. Nature Medicine 2024, 30: 2242-2250. PMID: 38824244, PMCID: PMC11333285, DOI: 10.1038/s41591-024-03060-0.Peer-Reviewed Original ResearchConceptsProgression-free survivalAntitumor activityEpidermal growth factor receptor-negativeBreast cancer preclinical modelsMedian progression-free survivalPhase 1 dose-escalationTreatment-related adverse eventsDose-expansion studyEstrogen receptor-positiveMetastatic breast cancerPhase 1 trialFirst-in-humanFulvestrant combinationReceptor-negativeReceptor-positiveEvaluation of antitumor activitySecondary endpointsPreclinical modelsSafety profileAdverse eventsBreast cancerApproximately doseClinical proofMonotherapyResponse rateLebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
Simpson E, de Bruin-Weller M, Hong H, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater A, Rueda M, Ding Y, Liu Z, Agell H, Silverberg J. Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology And Therapy 2024, 14: 1145-1160. PMID: 38700646, PMCID: PMC11116327, DOI: 10.1007/s13555-024-01158-4.Peer-Reviewed Original ResearchEczema Area and Severity IndexWeek 2Clinical signsHead and neck regionRefractory to treatmentBody regionsSeverity of ADClinical responseEczema AreaEfficacy measuresPlaceboAtopic dermatitisLebrikizumabNeck regionIntroductionAtopic dermatitisMonotherapyWeeksPost-hocErythemaPatientsSeveritySeverity IndexEczemaDermatitisLichenificationTopical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.
Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.Peer-Reviewed Original ResearchConceptsAcne vulgarisTopical clindamycinTreatment of acne vulgarisManagement of acne vulgarisEmergence of antibiotic-resistant bacteriaAntibiotic-resistant bacteriaTopical agentsAnti-inflammatory propertiesTherapeutic advancesClindamycinClinical studiesTherapeutic outcomesClinical applicationAntimicrobial profileGram-positive bacteriaAnaerobic bacteriaMode of actionVulgarisMonotherapyPublished dataBacteriaTherapyAcneAntibioticsEffectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis
Vydyam P, Chand M, Pou S, Winter R, Liebman K, Nilsen A, Doggett J, Riscoe M, Mamoun C. Effectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis. ACS Infectious Diseases 2024, 10: 1405-1413. PMID: 38563132, PMCID: PMC11127568, DOI: 10.1021/acsinfecdis.4c00143.Peer-Reviewed Original ResearchConceptsRadical cureEndochin-like quinolonesAgent of human malariaLethal infection modelTreatment of human babesiosisLow toxicity profileExperimental mouse modelImmunocompetent miceImmunocompromised miceFavorable pharmacological propertiesHuman malariaToxicity profileChronic modelHuman babesiosisAnimal modelsInfection modelPharmacological limitationsActivity in vitroPharmacological propertiesReduce infectionQuinolonesMiceMitochondrial electron transport chainFavorable physicochemical propertiesMonotherapy
2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
Bergaggio E, Tai W, Aroldi A, Mecca C, Landoni E, Nüesch M, Mota I, Metovic J, Molinaro L, Ma L, Alvarado D, Ambrogio C, Voena C, Blasco R, Li T, Klein D, Irvine D, Papotti M, Savoldo B, Dotti G, Chiarle R. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 2023, 41: 2100-2116.e10. PMID: 38039964, PMCID: PMC10793157, DOI: 10.1016/j.ccell.2023.11.004.Peer-Reviewed Original ResearchConceptsALK inhibitorsALK expressionChimeric antigen receptor TBest tumor antigensPromising clinical activityExpression of ALKMost normal tissuesHematologic malignanciesClinical activityMost neuroblastomasAnaplastic lymphoma kinase (ALK) receptorTherapeutic successTumor antigensPotent efficacySolid tumorsTherapeutic efficacyNeuroblastomaTumor growthOncogenic driversNeuroblastoma cellsNormal tissuesALKKinase receptorsMonotherapyInhibitors608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors
Chen C, Hamilton E, LoRusso P, Rottey S, Papadopoulos K, Kummar S, Kotecki N, Thistlethwaite F, LeBruchec Y, Dyczkowski J, Rüschoff J, Samari S, Toukam M, Boni J, Havenith K, Pantano S, Puzanov I. 608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors. 2023, a692-a692. DOI: 10.1136/jitc-2023-sitc2023.0608.Peer-Reviewed Original Research736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies
Moser J, Sullivan R, Taylor M, Puzanov I, Falchook G, Sznol M, Paton V, Chonzi D, Garofalo B, Sonnemann M, Uppal H, Barton J, McQueen B, Ring A, Kluger H. 736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies. 2023, a829-a829. DOI: 10.1136/jitc-2023-sitc2023.0736.Peer-Reviewed Original Research2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
Sridhar S, O'Donnell P, Flaig T, Rosenberg J, Hoimes C, Milowsky M, Srinivas S, George S, McKay R, Petrylak D, Barata P, Hwang C, Cruz-Correa M, Iafolla M, Mckean M, Dreicer R, Brancato S, Lukas J, Yu Y, Moon H. 2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC). Annals Of Oncology 2023, 34: s1203. DOI: 10.1016/j.annonc.2023.09.1014.Peer-Reviewed Original ResearchCombining Pharmacotherapy and Psychological Treatments for Obsessive-Compulsive Disorder
Tolin D, Sain K. Combining Pharmacotherapy and Psychological Treatments for Obsessive-Compulsive Disorder. 2023, 557-583. DOI: 10.1093/oxfordhb/9780190068752.013.21.Peer-Reviewed Original ResearchCognitive behavioral therapyObsessive-compulsive disorderD-cycloserineFirst-line monotherapyEffective monotherapyCombined therapyMedication monotherapyMonotherapyFirst treatmentSystematic reviewCBT monotherapyTherapyPsychological treatmentCompulsive disorderPharmacotherapyTreatmentMeta-analytic strategyBiological mechanismsDisordersEfficacyPlaceboMedicationsPatientsFirst-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer
Kim S, Gettinger S. First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 557-573. PMID: 37150586, DOI: 10.1016/j.hoc.2023.02.008.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerAdvanced non-small cell lung cancerFirst-line settingFirst-line treatmentStandard of careCombination immunotherapyImmunotherapy monotherapyPD-L1Immunotherapy responseLine treatmentSmoking statusTreatment choiceTrial dataCancerImmunotherapyRegimensCliniciansTreatmentChemoimmunotherapyMonotherapyCareP111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)
Harbeck N, Boileau J, Modi S, Kelly C, Ohno S, Wu J, Konpa A, Herbolsheimer P, Safdar S, Zhang Y, Pusztai L. P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11). The Breast 2023, 68: s57. DOI: 10.1016/s0960-9776(23)00228-x.Peer-Reviewed Original ResearchMolecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
Detappe A, Nguyen H, Jiang Y, Agius M, Wang W, Mathieu C, Su N, Kristufek S, Lundberg D, Bhagchandani S, Ghobrial I, Ghoroghchian P, Johnson J. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nature Nanotechnology 2023, 18: 184-192. PMID: 36702954, PMCID: PMC10032145, DOI: 10.1038/s41565-022-01310-1.Peer-Reviewed Original ResearchConceptsCombination therapyMultiple myelomaNarrow therapeutic indexMultiple myeloma therapyFree drug combinationFree drug counterpartsMyeloma therapySame doseTherapeutic indexTumor progressionBPD exhibitTherapyProteasome inhibitorsCombination nanomedicinesCancer therapyMonotherapyMyelomaSynergistic ratio
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply